Long-term mortality after PCI in patients with diabetes mellitus: results from the Swedish Coronary Angiography and Angioplasty Registry

被引:6
作者
Norhammar, Anna [1 ]
Lagerqvist, Bo [2 ]
Saleh, Nawsad [1 ]
机构
[1] Karolinska Univ Hosp, Cardiol Unit, Dept Med, Stockholm, Sweden
[2] Akad Univ Hosp, Dept Cardiol, Uppsala, Sweden
关键词
Percutaneous coronary intervention; diabetes mellitus; mortality; acute coronary syndrome; long-term prognosis; C-REACTIVE PROTEIN; MULTIVESSEL DISEASE; PLATELET ACTIVATION; 5-YEAR OUTCOMES; INTERVENTION; CLOPIDOGREL; RISK; PRETREATMENT; ABCIXIMAB; THERAPY;
D O I
10.4244/EIJV5I8A152
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: Patients with diabetes mellitus have poorer outcome following acute coronary syndromes and coronary revascularisation. Knowledge of long-term outcome after revascularisation in real-life situations is though limited was analysed. Methods and results: Patients included in the Swedish Coronary Angiography Angioplasty Registry (SCAAR) in 2002-2007 with no previous revascularisation were followed for mortality after a first PCI until the end of 2007 (mean follow-up time 1,059 days). Differences in background and procedural characteristics were adjusted for in a multivariable Cox regression model. Of 57,708 patients, 18.8% had diabetes. Absolute mortality rate after four years follow-up was after STEMI, non-ST-elevation ACS and stable CAD respectively 23.2%, 17.8% and 12.7% for persons with diabetes and 14.4%, 8.4% and 5.7% for persons without diabetes. Adjusted relative risk for long-term mortality after first PCI was higher in patients with diabetes compared with those without; RR (95% Cl); 1.66 (1.33-1.72), and after all three different PCI indications; RR (95% Cl) for CAD; 2.01 (1.69-2.40), non-ST-elevation ACS 1.73 (1.58-1.90) and STEMI 1.44(1.30-1.59). Conclusions: Long-term mortality is higher in diabetic patients compared with those without, after a first PCI and this mortality gap increases with follow-up time. Intensive secondary preventive measures are needed to improve this situation.
引用
收藏
页码:891 / 897
页数:7
相关论文
共 25 条
  • [1] Alderman EL, 1996, NEW ENGL J MED, V335, P217
  • [2] Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease
    Angiolillo, Dominick J.
    Bernardo, Esther
    Sabate, Manel
    Jimenez-Quevedo, Pilar
    Costa, Marco A.
    Palazuelos, Jorge
    Hernandez-Antolin, Rosana
    Moreno, Raul
    Escaned, Javier
    Alfonso, Fernando
    Banuelos, Camino
    Guzman, Luis A.
    Bass, Theodore A.
    Macaya, Carlos
    Fernandez-Ortiz, Antonio
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (16) : 1541 - 1547
  • [3] Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease - Results of the Optimizing antiPlatelet Therapy In diabetes MellitUS (OPTIMUS) study
    Angiolillo, Dominick J.
    Shoemaker, Steven B.
    Desai, Bhaloo
    Yuan, Hang
    Charlton, Ronald K.
    Bernardo, Esther
    Zenni, Martin M.
    Guzman, Luis A.
    Bass, Theodore A.
    Costa, Marco A.
    [J]. CIRCULATION, 2007, 115 (06) : 708 - 716
  • [4] Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment
    Angiolillo, Dominick J.
    Bernardo, Esther
    Ramirez, Celia
    Costa, Marco A.
    Sabate, Manel
    Jimenez-Quevedo, Pilar
    Hernandez, Rosana
    Moreno, Raul
    Escaned, Javier
    Alfonso, Fernando
    Banuelos, Camino
    Bass, Theodore A.
    Macaya, Carlos
    Fernandez-Ortiz, Antonio
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (02) : 298 - 304
  • [5] An increase in HbA1c after percutaneous coronary intervention raises the risk for restenosis in patients without Type 2 diabetes mellitus
    Diedrichs, H.
    Pfister, R.
    Hagemeister, J.
    Mueller-Ehmsen, J.
    Frank, K. F.
    Hoepp, H. -W.
    Erdmann, E.
    Schneider, C. A.
    [J]. DIABETIC MEDICINE, 2008, 25 (02) : 228 - 231
  • [6] Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes
    Eibl, N
    Krugluger, W
    Streit, G
    Schrattbauer, K
    Hopmeier, P
    Schernthaner, G
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2004, 34 (03) : 205 - 209
  • [7] Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) trial
    Farkouh, Michael E.
    Dangas, George
    Leon, Martin B.
    Smith, Craig
    Nesto, Richard
    Buse, John B.
    Cohen, David J.
    Mahoney, Elizabeth
    Sleeper, Lynn
    King, Spencer, III
    Domanski, Michael
    McKinlay, Sonja
    Fuster, Valentin
    [J]. AMERICAN HEART JOURNAL, 2008, 155 (02) : 215 - 223
  • [8] Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with Type II diabetes mellitus
    Gresele, P
    Guglielmini, G
    De Angelis, M
    Ciferri, S
    Ciofetta, M
    Falcinelli, E
    Lalli, C
    Ciabattoni, G
    Davì, G
    Bolli, GB
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 1013 - 1020
  • [9] Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials
    Iijima, R.
    Byrne, R. A.
    Ndrepepa, G.
    Braun, S.
    Mehilli, J.
    Berger, P. B.
    Schoemig, A.
    Kastrati, A.
    [J]. HEART, 2009, 95 (02) : 107 - 112
  • [10] Silent myocardial ischemia in patients with diabetes - who to screen
    Janand-Delenne, B
    Savin, B
    Habib, G
    Bory, M
    Vague, P
    Lassmann-Vague, V
    [J]. DIABETES CARE, 1999, 22 (09) : 1396 - 1400